The Significance of Antiphospholipid Antibodies in Pregnant Women with Chronic Hypertension

The objective of this study was to perform antiphospholipid antibody screening in women with chronic hypertension to assess whether the presence of such antibodies is associated with adverse pregnancy outcome. Serum for anticardiolipin antibodies and lupus anticoagulant was obtained in pregnant women with chronic hypertension who had no other indications for such testing. The primary outcomes of interest were the development of superimposed preeclampsia, preterm delivery, and fetal growth restriction. Only 8 (9%) of the 87 women enrolled tested positive (> 95th percentile) for anticardiolipin immunoglobulin G. None tested positive for lupus anticoagulant. The presence of antiphospholipid antibodies was not associated with adverse pregnancy outcome. We were unable to demonstrate that screening for antiphospholipid antibodies is a useful clinical practice in women whose only pregnancy complication was chronic hypertension. The significance of such antibodies in this particular group of patients can only be resolved with a large multicenter study.

KEYWORDS

Antiphospholipid antibody - chronic hypertension - preeclampsia

REFERENCES

• 1 Branch D W, Scott J R, Kochenour N K, Hershgold E. Obstetric complications associated with the lupus anticoagulant.  N Engl J Med. 1985;  313 1322-1326
• 2 Branch D W, Silver R M, Blackwell J L, Reading J C, Scott J R. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience.  Obstet Gynecol. 1992;  80 614-620
• 3 Lockwood C J, Romero R, Feinberg R F, Clyne L P, Coster B, Hobbins J C. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population.  Am J Obstet Gynecol. 1989;  161 369-373
• 4 Lima F, Khamashta M A, Buchanan N M, Kerslake S, Hunt B J, Hughes G R. A study of sixty pregnancies in patients with the antiphospholipid syndrome.  Clin Exp Rheumatol. 1996;  14 131-136
• 5 Antiphospholipid syndrome .ACOG Educational Bulletin no. 244. Washington, DC; ACOG February 1998
• 6 Levine J S, Branch D W, Rauch J. The antiphospholipid syndrome.  N Engl J Med. 2002;  346 752-763
• 7 Branch D W, Porter T F, Rittenhouse L et al.. Antiphospholipid antibodies in women at risk for preeclampsia.  Am J Obstet Gynecol. 2001;  184 825-832
• 8 Pattison N S, Chamley L W, Birdsall M, Zanderigo A M, Liddell H S, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial.  Am J Obstet Gynecol. 2000;  183 1008-1012
• 9 Rai R, Cohen H, Dave M, Refan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).  BMJ. 1997;  314 253-257
• 10 Harris E N. The second international anticardiolipin standardization workshop: the Kingston antiphospholipid antibody study (KAPS) group.  Am J Clin Pathol. 1990;  94 476-484
• 11 Parry S, Macones G A, Roth N W, Desperito T J, Marzullo A, Morgan M A. Antiphospholipid antibodies in chronic hypertension: the value of screening during pregnancy.  Am J Perinatol. 1998;  15 527-531